|
|
Support : Dialog Search Aids
: Pharmaprojects Therapeutic Class Codes
Pharmaprojects Therapeutic Class Codes
(DIALOG Files 128*, 928*)
*(Subscriber access.)
 View the PDF version of this document
This list includes the therapeutic categories
in order of their codes. This allows you to
see the hierarchy involved in the classification.
| K |
ANTICANCER PRODUCTS |
| K1A |
ANTICANCER, ANTIBIOTIC
Natural and semisynthetic antibiotics and their derivatives, which have anticancer activity. Agents under investigation include actinomycins eg topisomerase II inhibitors, anthracyclines eg doxorubicin analogues, bleomycin derivatives and mitomycin analogues. |
| K1B |
ANTICANCER, ALKYLATING
Alkylating anticancer compounds act by forming highly reactive carbonium ions which replace an H-atom with an alkyl radical, causing cross-linking and abnormal base-pairing in DNA molecules. Agents under development include nitrogen mustards, alkyl sulfonates, nitroureas, triazenes and platinum-containing products. |
| K1C |
ANTICANCER, ANTIMETABOLITE
Antimetabolites impair the synthesis of purine and pyrimidine bases by interfering with folic acid metabolism or by preventing the incorporation of the bases into nucleic acids. Products under investigation include antifolates eg dihydrofolate reductase (DHFR) inhibitors, pyrimidine analogues eg thymidylate synthetase inhibitors, purine analogues and inhibitors of S-adenosylmethionine decarboxylase and tyrosine kinase. |
| K2 |
ANTICANCER, HORMONAL
Hormones or their analogues which have anticancer activities and also compounds which have antagonist activity to hormones. Agents which are specifically under development for the treatment of hormone-dependent tumours. Products under development include estrogens, antiestrogens, progestogens, antiprogestogens, antiandrogens, releasing hormone analogues and somatostatin analogues. |
| K3 |
ANTICANCER, IMMUNOLOGICAL
Immunomodulating compounds which are being developed as anticancer agents (except for interferons (K4)) including cytokines, such as interleukins, transforming growth factors (TGF), tumour necrosis factors (TNF) and colony stimulating factors (CSF). Also includes monoclonal antibodies (MAbs) and immunotoxins which are used to target and treat cancer, and conjugates of anticancer agents with MAbs. |
| K4 |
ANTICANCER, INTERFERON
Recombinant, natural and synthetic interferons used in the treatment of cancer including a -, b — and g -interferons and interferon inducers. |
| K5A |
RADIO/CHEMOSENSITIZER
Compounds that improve the efficacy of radiotherapy and chemotherapy by sensitizing the cells. Also multidrug-resistance inhibitors (MDRI) for use in combination with cancer chemotherapy. |
| K5B |
RADIO/CHEMOPROTECTIVE
Products which protect tissues or organs from the damaging effects of radiation and chemotherapy. Growth factors and interleukins which stimulate red and white blood cell production and thus protect against chemotherapy- or radiation-induced anaemia and leucopenias. A number of cytokines are being developed as radio/chemoprotectants including various recombinant granulocyte macrophage CSF (GM-CSF), M-CSF and CSF, recombinant IL-1a , IL-3 and IL-7. |
| K6Z |
ANTICANCER, OTHER
General anticancer agents for which the mode of action is unknown or those which do not come under the other anticancer categories (except Radio/chemosensitizer (K5A) and Radio/chemoprotective (K5B)). Products in development include vinka alkaloids and asparaginase carriers. |
Last modified on 24 Feb 2012.
top
|
Related Search Aid:
Pharmaprojects (DIALOG Files 128, 928) Major Events in the Update Information (UP) Field
|
Dialog1
Support Home